Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

FDA grants Fast Track designation to Johnson & Johnson’s investigational therapy nipocalimab for the treatment of moderate-to-severe Sjögren’s disease, which could be the first targeted therapy ever ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

The ambulatory infusion suite is operated by registered nurses who specialise in treating patients with complex conditions.

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) is expected to be issuing its quarterly earnings data before the market ...

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Tuesday, March 25th. Analysts expect the company to announce ...

Batoclimab is an anti-FcRn treatment being developed for a range of autoimmune diseases and active thyroid eye disease (TED).

The winners of The Bupa everywoman in Technology Awards, have been announced. Now in their 15th year, the awards celebrate outstanding contributions and achievements at all stages of the career ...

J'JO doesn't handle users' funds: Users aren't required to transfer their funds to J'JO as all investments and assets remain ...

The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but ...